EVENT DOSSIER
On September 8, 2026, Rentosertib, an AI-generated drug developed by InSight AI, was first introduced into human clinical trials. This drug is targeted at idiopathic pulmonary fibrosis and aims to extend lifespan by delaying the aging process. A total of 43 patients participated in the trial. After 12 consecutive weeks of medication, the predicted age calculated based on cell, tissue, and organ functions decreased significantly, and all six “aging clock” measurements showed reduced predicted ages for the patients. One study noted that this was the first study to clearly demonstrate that predicting biological age can reduce it. Although the sample size was small and the drug was not tested in healthy populations, experts said this study provides a model for future research in longevity.
英矽智能研发的 AI 生成药物 Rentosertib 首次进入人体临床试验，结果显示患者体内与年龄相关的生物标志物下降。该药针对特发性肺纤维化，分子结构由 AI 辅助生成，旨在从整体上延长寿命。共有 43 名患者参与试验，连续服药 12 周后，基于细胞、组织和器官功能状况推算的预测年龄显著下降。6 种“衰老时钟”测量均显示患者预测年龄降低，其中一项研究指出这是第一项明确显示预测生物年龄可降低的研究。尽管样本规模较小且药物未在健康人群中测试，专家称该研究为未来长寿领域提供了范本。